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Training Tomorrow’s Providers and Expanding Access to Peginterferon/Ribavirin Combination Therapy
for Chronic Hepatatis C in Underinsured/Uninsured Patients:
Final Outcomes of a Pilot, Resident-Initiated, Multidisciplinary, Hepatitis C Clinic
Nicole Agostino DO, Suzanne J. Templer DO, Edward R. Norris MD, Charles M. Brooks MD, Eric J. Gertner MD, MPH, and Joseph L. Yozviak DO
Lehigh Valley Health Network, Allentown, Pennsylvania

Introduction:

Results:

Clinical trials have shown that at least 40% of patients with chronic
hepatitis C (HCV) achieve sustained virologic response (SVR) with
peginterferon-alfa/ribavirin (Peg/RBV) therapy along with adequate
medical and psychiatric support. Despite the availability of potentially
curative therapy, a lack of insurance or inadequate insurance may
prevent access to this treatment for many patients. Another potential
barrier is the relatively small pool of physicians capable and willing
to provide Peg/RBV therapy. SVR is achieved less often in clinical
practice than in research trials, where patients with a history of mental
illness or multiple medical comorbidities are commonly excluded.
We proposed that an integrated, multidisciplinary approach to Peg/
RBV therapy would result in SVR rates similar to those of clinical trials
in a medically and psychiatrically complex cohort of patients, while
training internal medicine residents to provide this therapy.

Table 1: Demographics (All Patients, N=48)
Gender

Male
Female

Age (mean)

45.0 Years

Weight of Treated Patients (mean)

191.3 lbs

Baseline Viral Load

>400,000 IU
<400,000 IU
Not available

Preexisting Psychiatric Diagnosis

38 (79%)

15 (31%)
33 (69%)

29 (60%)
16 (33%)
3 (6%)

Figure 1: Genotype Distribution of Treated Patients (N=26)
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Methods:
A pilot HCV clinic was established in 2004, staffed by internal
medicine residents, an attending gastroenterologist and psychiatrist,
and a registered-nurse coordinator. All patients were underinsured/
uninsured and underwent peginterferon alfa-2a/RBV therapy.
The length of therapy was 48 weeks for genotypes 1 and 4, and
24 weeks for genotypes 2 and 3. Medical residents participated
actively throughout Peg/RBV therapy by performing initial patient
assessments and providing follow-up care including the management
of medical and psychiatric side effects. The initial cohort completed
follow-up in early 2008. Charts were retrospectively abstracted for
demographics and baseline characteristics, virologic response, side
effects, and reasons for discontinuation or non-initiation of therapy.

•	Eight medical residents volunteered to participate in monthly HCV
clinics over 3 years.
•	Forty-eight patients were evaluated. None were co-infected with
human immunodeficiency virus (HIV).
•	Twenty-six patients (54%) were treated. Twenty-two (46%) were not
appropriate candidates for therapy. Personal choice was the reason
cited by 46% of those not treated, followed by unstable psychiatric
illness (27%), comorbidities (18%), substance abuse (9%), viral
clearance (9%), lack of follow-up (4%), and minimal fibrosis (4%).
•	Ten (38.5%) treated patients achieved sustained virologic response in
this mainly genotype 1-infected cohort.
•	Thirteen patients discontinued therapy. Side effects were the most
commonly reported reason for discontinuation (23%) followed by
virologic null response, which occurred in 5 patients (19%). Other
reasons cited were psychiatric (3%), poor adherence (3%), ongoing
substance abuse (3%), and incarceration (3%).

CONCLUSIONS:
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84 %

Figure 3: Most Commonly Reported
Adverse Events

Figure 2: Outcomes of Peg/RBV Therapy
(N=26)
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Despite a patient population with mostly genotype 1 HCV and
significant medical/psychiatric comorbidities, we were able to achieve
ETR/SVR rates comparable to those commonly reported. These
data suggest that an integrative medicine practice can safely and
effectively manage Peg/RBV therapy and serve as a model to expand
access to antiviral therapy for many individuals with chronic HCV.
Additionally, by incorporating a dedicated group of internal medicine
residents, the pool of capable and willing providers of Peg/RBV
therapy will be expanded.
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